Drug
Dordaviprone
Dordaviprone: highest development phase Phase 2, developed by Jazz Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dordaviprone (ONC201) NCT03295396 | Phase 2 | Glioma |
| Dordaviprone (ONC201) NCT03485729 | Phase 2 | Endometrial Cancer Recurrent |
Latest
No recent events.
Follow Dordaviprone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.